Real-world data collection on vericiguat treatment in patients with heart failure to study the behavior of the medicine.

Retrospective, non-interventional database study for the evaluation of real-world drug use patterns, clinical characteristics and clinical outcomes in patients initiated on Vericiguat in India - NIL

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2025/07/090940

Enrollment

1200

Registered

2025-07-15

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I508- Other heart failure

Interventions

Intervention1: Vericiguat: Patients who have been prescribed Vericiguat 2.5 mg Vericiguat 5 mg Vericiguat 10 mg from 1st Sep 2022 until 31st Aug 2023 Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Patients of >=18 years age. Patients who are prescribed as per local label will be included in the study. At least one Vericiguat prescription during the time between 1st Sep2022 and 31st Aug 2023.

Exclusion criteria

Exclusion criteria: Subjects who have participated in an interventional clinical study.

Design outcomes

Primary

Measure	Time frame
To describe the baseline clinical characteristics e.g., demographics, concomitant medication, medical history and surgical history, history of hospitalization, NT-proBNP levels) & treatment patterns of patients initiated on Vericiguat. â?¢ To describe the use of medications of interest (yes/no) before/after initiation of Vericiguat as well as the prescribed amount of medications in respective periods. â?¢ To describe the measures for titration patterns (Starting dose, up-titration / down-titration (yes/no), time until target dose). â?¢ To describe the no. of patients who have discontinued treatment, time points of discontinuation, reasons for discontinuation (Symptomatic hypotension, syncope). Timepoint: 6 months	—

Measure

Time frame

To describe the baseline clinical characteristics e.g., demographics, concomitant medication, medical history and surgical history, history of hospitalization, NT-proBNP levels) & treatment patterns of patients initiated on Vericiguat. â?¢ To describe the use of medications of interest (yes/no) before/after initiation of Vericiguat as well as the prescribed amount of medications in respective periods. â?¢ To describe the measures for titration patterns (Starting dose, up-titration / down-titration (yes/no), time until target dose). â?¢ To describe the no. of patients who have discontinued treatment, time points of discontinuation, reasons for discontinuation (Symptomatic hypotension, syncope). Timepoint: 6 months

—

Secondary

Measure	Time frame
To describe the clinical outcome of patients initiated on Vericiguat in real world setting. â?¢ Hospitalization rate due to HF after Vericiguat initiation â?¢ CV mortality rate â?¢ Composite of HF hospitalization and CV mortality â?¢ Overall frequency and incidence of symptomatic hypotension and syncope after vericiguat initiationTimepoint: 6 months	—

Countries

India

Contacts

Public ContactDr Disha Gupta

Bayer Pharmaceuticals Private Limited

disha.gupta@bayer.com8724030192

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026